Neurobehavioral Disorders
Data for this study were sourced from 4 active treatment arms of 4 randomized, controlled trials conducted by the National Institutes of Health in the United States between 2006 and 2018.
Neurobehavioral Disorders
Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.
Neurobehavioral Disorders
A model comprising 6 clinical variables could be used to guide lithium dosage.
Alzheimer's Disease and Dementia
Researchers sought to assess the clinical prevalence of Alzheimer disease in patients with leprosy, also known as Hansen’s disease, and inflammasome activity.
Neurocognitive Disorders
In a case-control study, researchers assessed the potential link between late-onset depression and the risk of developing major cognitive disorder.
Multiple Sclerosis
In a prospective cohort study, researchers assessed whether adverse childhood experiences may increase the risk for multiple sclerosis in women.
Neurobehavioral Disorders
The US Preventive Services Task Force (USPSTF) recommends screening for major depressive disorder (MDD) in adolescents aged 12 to 18 years, and recommends anxiety screening for children aged 8 to 18 years.
Neurobehavioral Disorders
The researchers of this study explored the impact of a blended approach (bCBT) that included both face-to-face CBT and iCBT on patients with major depressive disorder and insomnia.
Neurobehavioral Disorders
Researchers examined the effect of neuropeptides orexin-A, ghrelin, and neuropeptide Y on hypersomnia and hyperphagia. Both symptoms are more common in people with bipolar disorder.
HowToTreat
Spinal muscular atrophy is one of the most common causes of infant mortality. Historically, SMA treatment consisted of supportive care only. The arrival of disease-modifying therapies has made a major impact on the prognosis for patients with SMA. This article highlights therapies approved by the FDA, such as survival motor neuron 2 (SMN2) modulators, SMN1 gene therapy, and the use of newborn screening to commence treatment in the pre-symptomatic period.
